Market Overview

Cancer Genetics Shares Rally As Feltl Analyst Getting More Bullish

Related CGIX
Cancer Genetics Expands Market Share In Immuno-Oncology Focused Clinical Studies
Cancer Genetics to Report Biomarker Findings in Metastatic Clear Cell Renal Carcinoma Using a CGI-Designed NGS Panel
Margins Are Key For NeoGenomics In Q2 2016 (Seeking Alpha)

Shares of Cancer Genetics (NASDAQ: CGIX) are on the move Wednesday morning following some positive comments and a raised price target from Feltl & Co.'s Ben Haynor. The analyst now sees Cancer Genetics shares rising to $30.50 over the next year, up from $17.50 previously.

The Feltl analyst cited a recent meeting with the company's CEO Panna Sharma on a non-deal roadshow earlier this week. Haynor believes a number of factors validated Cancer Genetics' "platform and go-to-market strategy."

  • Expanded relationship between the company and Roche for the ExpandDx community hospital program.
  • Expected added patents for the typing, profiling of blood cancers.
  • The company remains on track to unveil the MCL array, FHACT during the last few months of 2013.
  • A belief by management the company is "e in the top tier of firms oncology sales specialists would come to, a distinct change from earlier in the year."

Haynor reiterated a Strong Buy rating on shares of Cancer Genetics.

The stock last traded at $20.67; shares pushed to a session high of $22.59. Haynor's new price target represents potential upside of nearly 50 percent from where the stock is currently trading.

Latest Ratings for CGIX

Mar 2016Aegis CapitalMaintainsBuy
Mar 2016Janney CapitalDowngradesBuyNeutral
Apr 2015Janney CapitalInitiates Coverage onBuy

View More Analyst Ratings for CGIX
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration Analyst Ratings Movers


Related Articles (CGIX)

View Comments and Join the Discussion!